KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments (2016 - 2017)

Jazz Pharmaceuticals (JAZZ) has 3 years of Short-Term Debt repayments data on record, last reported at -$350.0 million in Q4 2017.

  • For Q4 2017, Short-Term Debt repayments fell 333.33% year-over-year to -$350.0 million; the TTM value through Sep 2018 reached -$350.0 million, down 135.0%, while the annual FY2020 figure was $500.0 million, N/A changed from the prior year.
  • Short-Term Debt repayments reached -$350.0 million in Q4 2017 per JAZZ's latest filing, down from $500.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $500.0 million in Q3 2017 and bottomed at -$350.0 million in Q4 2017.
  • Average Short-Term Debt repayments over 3 years is $121.7 million, with a median of $150.0 million recorded in 2016.
  • Peak YoY movement for Short-Term Debt repayments: surged 87.5% in 2016, then plummeted 333.33% in 2017.
  • A 3-year view of Short-Term Debt repayments shows it stood at $80.0 million in 2015, then soared by 87.5% to $150.0 million in 2016, then plummeted by 333.33% to -$350.0 million in 2017.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt repayments were -$350.0 million in Q4 2017, $500.0 million in Q3 2017, and $200.0 million in Q2 2017.